Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action

Neurourology and Urodynamics

Volumn 30, Issue 3, 2011, Pages 292-301

  Andersson, Karl Erik ^a   De Groat, William C ^b   McVary, Kevin T ^c   Lue, Tom F ^d   Maggi, Mario ^e   Roehrborn, Claus G ^f   Wyndaele, Jean Jacques ^g   Melby, Thomas ^h   Viktrup, Lars ⁱ  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF ANTWERP   (Belgium)

^h Medical Writing   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

PDE5 phosphodiesterases; Prostatic hyperplasia; Urinary tract

Indexed keywords

ANDROGEN; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SILDENAFIL; TADALAFIL; VARDENAFIL;

ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM; BLADDER; CELL PROLIFERATION; CHRONIC INFLAMMATION; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; KIDNEY ISCHEMIA; LOWER URINARY TRACT SYMPTOM; NERVE CONDUCTION; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; SENSORY NERVE; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE RELAXATION; TISSUE PERFUSION; UPREGULATION; URETHRA;

CARBOLINES; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; URODYNAMICS; UROLOGIC DISEASES;

EID: 79952749220     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20999     Document Type: Review

References (122)

1. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49. (Pubitemid 37542920)
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49. (Pubitemid 36151708)
3. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol 2006;49:651-8. (Pubitemid 43374725)
4. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50:1306-14.
5. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001;58:5-16. (Pubitemid 34007591)
6. Abdel-Aziz KF, Lemack GE. Overactive bladder in the male patient: Bladder, outlet, or both? Curr Urol Rep 2002;3:445-51.
7. Andersson KE. Storage and voiding symptoms: Pathophysiologic aspects. Urology 2003;62:3-10.
8. Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: A systematic review of the latest literature. Eur Urol 2009;56:810-20.
9. Chapple CR, Wein AJ, Abrams P, et al. Lower urinary tract symptoms revisited: A broader clinical perspective. Eur Urol 2008;54:563-9.
10. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. http://www.auanet.org/content/guidelinesand-quality-care/ clinical-guidelines/main-reports/bph-management/chapt-3-appendix.pdf, 2003.
11. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98. (Pubitemid 37542987)
12. Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009;55:38-48.
13. McVary K. Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. BJU Int 2006;97:23-8. (Pubitemid 43356992)
14. Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53:1236-44.
15. McVary KT, Monnig W, Camps JL Jr, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007;177:1071-7. (Pubitemid 46216352)
16. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7. (Pubitemid 46435965)
17. Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008;180:1228-34.
18. Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010; 105:502-7.
19. Donatucci C, Brock G, Goldfischer E, et al. Tadalafil administered once daily for treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A 1-year study. BJU Int 2010 (in press).
20. Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: A randomized, placebo controlled 12-week clinical trial. J Urol 2010;183:1092-7.
21. Kedia GT, Uckert S, Jonas U, et al. The nitric oxide pathway in the human prostate: Clinical implications in men with lower urinary tract symptoms. World J Urol 2008;26:603-9.
22. Andersson KE, Uckert S, Stief C, et al. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 2007;26:928-33. (Pubitemid 47548230)
23. Roumeguere T, Zouaoui Boudjeltia K, Hauzeur C, et al. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU Int 2009;104:511-7.
24. Tinel H, Stelte-Ludwig B, Hutter J, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1259-63. (Pubitemid 44721238)
25. Hedlund P, Ekstrom P, Larsson B, et al. Heme oxygenase and NO-synthase in the human prostate-relation to adrenergic, cholinergic and peptidecontaining nerves. J Auton Nerv Syst 1997;63:115-26. (Pubitemid 27168871)
26. Bloch W, Klotz T, Loch C, et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997;33:1-8. (Pubitemid 27381587)
27. Uckert S, Kuthe A, Jonas U, et al. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166:2484-90. (Pubitemid 33065340)
28. Persson K, AlmP, Johansson K, et al. Co-existence of nitrergic, peptidergic and acetylcholine esterase-positive nerves in the pig lower urinary tract. J Auton Nerv Syst 1995;52:225-36.
29. Gillespie JI, Markerink-van Ittersum M, de Vente J. Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res 2005;321:341-51. (Pubitemid 41206988)
30. Gillespie JI, Markerink-van Ittersum M, de Vente J. Endogenous nitric oxide/ cGMP signalling in the guinea pig bladder: Evidence for distinct populations of sub-urothelial interstitial cells. Cell Tissue Res 2006;325:325-32. (Pubitemid 44050798)
31. Birder LA, Apodaca G, de Groat WC, et al. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 1998;275:F226-9.
32. Garcia-Pascual A, Sancho M, Costa G, et al. Interstitial cells of Cajal in the urethra are cGMP-mediated targets of nitrergic neurotransmission. Am J Physiol Renal Physiol 2008;295:F971-83.
33. de Jongh R, van Koeveringe GA, van Kerrebroeck PE, et al. Alterations to network of NO/cGMP-responsive interstitial cells induced by outlet obstruction in guinea-pig bladder. Cell Tissue Res 2007;330:147-60.
34. Andersson KE, Garcia Pascual A, Persson K, et al. Electrically-induced, nerve-mediated relaxation of rabbit urethra involves nitric oxide. J Urol 1992;147:253-9.
35. Werkstrom V, Persson K, Ny L, et al. Factors involved in the relaxation of female pig urethra evoked by electrical field stimulation. Br J Pharmacol 1995;116:1599-604.
36. Werkstrom V, Svensson A, Andersson KE, et al. Phosphodiesterase 5 in the female pig and human urethra: Morphological and functional aspects. BJU Int 2006;98:414-23.
37. Truss MC, Uckert S, Stief CG, et al. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 1996;24:129-34.
38. Fujiwara M, Andersson K, Persson K. Nitric oxide-induced cGMP accumulation in the mouse bladder is not related to smooth muscle relaxation. Eur J Pharmacol 2000;401:241-50. (Pubitemid 30488203)
39. Kajioka S, Nakayama S, Seki N, et al. Oscillatory membrane currents paradoxically induced via NO-activated pathways in detrusor cells. Cell Calcium 2008;44:202-9.
40. Uckert S, Oelke M, Stief CG, et al. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006;49:740-5. (Pubitemid 43374744)
41. Fibbi B, Morelli A, Vignozzi L, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7:59-69.
42. Lin G, Hunag YC, Wang G, et al. Prominent expression of phosphodiesterase 5 in the striated muscle of rate urethra and levator ani. J Urol 2010;184:769-74.
43. Truss MC, Stief CG, Uckert S, et al. Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 2000;18:439-43.
44. Truss MC, Stief CG, Uckert S, et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: From bench to bedside. World J Urol 2001;19:344-50. (Pubitemid 33777080)
45. Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-29.
46. Werkstrom V, Hedlund P, Lee T, et al. Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder. BJU Int 2009;104:1740-5.
47. Bittencourt JA, Tano T, Gajar SA, et al. Relaxant effects of sildenafil on the human isolated bladder neck. Urology 2009;73:427-30.
48. Cinar A, Hall SA, Link CL, et al. Cluster analysis and lower urinary tract symptoms in men: Findings from the Boston Area Community Health Survey. BJU Int 2008;101:1247-56. (Pubitemid 351549637)
49. Coyne KS, Kaplan SA, Chapple CR, et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int 2009;103:24-32.
50. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts male aging study. Prev Med 2000;30:328-38. (Pubitemid 30211093)
51. Klotz T, Mathers MJ, BlochW, et al. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999;31:335-41. (Pubitemid 30041837)
52. Persson K, Igawa Y, Mattiasson A, et al. Inhibition of the arginine/nitric oxide pathway causes bladder hyperactivity in the rat. Acta Physiol Scand 1992;144:107-8.
53. Pandita RK, Mizusawa H, Andersson KE. Intravesical oxyhemoglobin initiates bladder overactivity in conscious, normal rats. J Urol 2000;164:545-50. (Pubitemid 30481981)
54. Persson K, Pandita RK, Aszodi A, et al. Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I. Am J Physiol Regul Integr Comp Physiol 2000;279:R1112-20.
55. Soler R, Fullhase C, Lu B, et al. Bladder dysfunction in a new mutant mouse model with increased superoxide - Lack of nitric oxide? J Urol 2010;183:780-5.
56. Guh JH, Hwang TL, Ko FN, et al. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998;53:467-74.
57. Morelli A, Filippi S, Sandner P, et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009;6:1594-608.
58. Bing W, Chang S, Hypolite JA, et al. Obstruction-induced changes in urinary bladder smooth muscle contractility: A role for Rho kinase. Am J Physiol Renal Physiol 2003;285:F990-7.
59. Chitaley K, Wingard CJ, Clinton Webb R, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001;7:119-22. (Pubitemid 32095651)
60. Marinese D, Patel R, Walden PD. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 2003;54:230-7. (Pubitemid 36120321)
61. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44. (Pubitemid 32771319)
62. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29-36. (Pubitemid 29278945)
63. Kupelian V, McVary KT, Kaplan SA, et al. Association of lower urinary tract symptoms and the metabolic syndrome: Results from the Boston Area Community Health Survey. J Urol 2009;182:616-24.
64. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: Linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010;70:79-89.
65. McVary KT, Rademaker A, Lloyd GL, et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005;174:1327-433.
66. Thor PJ, Mazur M, Furgala A, et al. The autonomic nervous system function in benign prostatic hyperplasia. Folia Med Cracov 2006;47:79-86.
67. Ullrich PM, Lutgendorf SK, Kreder KJ. Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia. Urology 2007;70:487-91. (Pubitemid 47464520)
68. McVary KT, Razzaq A, Lee C, et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994;51:99-107. (Pubitemid 24179226)
69. Wang JM, McKenna KE, McVary KT, et al. Requirement of innervation for maintenance of structural and functional integrity in the rat prostate. Biol Reprod 1991;44:1171-6.
70. McVary KT, McKenna KE, Lee C. Prostate innervation. Prostate Suppl 1998;8:2-13. (Pubitemid 28347989)
71. Golomb E, Rosenzweig N, Eilam R, et al. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000;21:58-64. (Pubitemid 30069082)
72. Persson K, Pandita RK, Spitsbergen JM, et al. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998;275:R1366-73.
73. de Groat WC, Yoshimura N. Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol 2009;194:91-138.
74. Steers WD, Ciambotti J, Etzel B, et al. Alterations in afferent pathways from the urinary bladder of the rat in response to partial urethral obstruction. J Comp Neurol 1991;310:401-10.
75. Steers WD, Kolbeck S, Creedon D, et al. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 1991;88:1709-15.
76. Steers WD, Creedon DJ, Tuttle JB. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol 1996;155:379-85. (Pubitemid 126426498)
77. Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008;72:104-8.
78. Steers WD, Tuttle JB. Mechanisms of disease: The role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006;3:101-10. (Pubitemid 43239267)
79. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:85M-93M.
80. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol 2006;50:721-31. (Pubitemid 44332685)
81. Berger AP, Deibl M, Leonhartsberger N, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 2005;96:1073-8. (Pubitemid 41531417)
82. Berger AP, Bartsch G, Deibl M, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006;98:1038-42. (Pubitemid 44536455)
83. Ghafar MA, Puchner PJ, Anastasiadis AG, et al. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 2002;3:292-6.
84. Berger AP, Kofler K, Bektic J, et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003;57:57-65. (Pubitemid 37070150)
85. Du Z, Fujiyama C, Chen Y, et al. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl) 2003;116:1936-9. (Pubitemid 38159901)
86. Lekas AG, Lazaris AC, Chrisofos M, et al. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology 2006;68: 436-41. (Pubitemid 44175515)
87. Azadzoi KM, Tarcan T, Kozlowski R, et al. Overactivity and structural changes in the chronically ischemic bladder. J Urol 1999;162:1768-78. (Pubitemid 29474727)
88. Azadzoi KM, Tarcan T, Siroky MB, et al. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J Urol 1999;161:1626-35. (Pubitemid 29420853)
89. Azadzoi KM, Yalla SV, Siroky MB. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol 2007;178:710-5. (Pubitemid 47030477)
90. Masuda H, Kihara K, Saito K, et al. Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int 2008;101:775-80. (Pubitemid 351269997)
91. Pinggera GM, Mitterberger M, Pallwein L, et al. alpha-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 2008;101:319-24.
92. Okutsu H, Matsumoto S, Hanai T, et al. Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 2010;75:235-40.
93. Mitterberger M, Pallwein L, Gradl J, et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int 2007;99:831-5. (Pubitemid 46439584)
94. Kershen RT, Azadzoi KM, Siroky MB. Blood flow, pressure and compliance in the male human bladder. J Urol 2002;168:121-5. (Pubitemid 34640796)
95. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007;51:1202-16.
96. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002;52:43-58. (Pubitemid 34553191)
97. Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008;35:109-115. (Pubitemid 350166524)
98. Robert G, Descazeaud A, Nicolaiew N, et al. Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 2009; 69:1774-80.
99. Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: Results from the MTOPS Study [Abstract 1286]. J Urol 2005;173:390.
100. Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2009;33:475-8.
101. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010;7:46-56.
102. Yang R, Huang YC, Lin G, et al. Lack of direct androgen regulation of PDE5 expression. Biochem Biophys Res Commun 2009;380:758-62.
103. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002;19:413-25.
104. Kedia GT, Uckert S, Kedia M, et al. Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology 2009;73:1397-401.
105. Uckert S, Sormes M, Kedia G, et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008;71:526-30. (Pubitemid 351374723)
106. Kang KK, Kim JM, Yu JY, et al. Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia. Int J Urol 2007;14:946-51. (Pubitemid 47429170)
107. Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009;55:38-48.
108. Yoshimura N, Seki S, de Groat WC. Nitric oxidemodulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol 2001;86:304-11.
109. Artim DE, Kullmann FA, Daugherty SL, et al. Activation of the nitric oxidecGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G. Am J Physiol Renal Physiol 2009;297:F333-40.
110. Beamon CR, Mazar C, Salkini MW, et al. The effect of sildenafil citrate on bladder outlet obstruction: A mouse model. BJU Int 2009;104:252-6.
111. Gacci M, Del Popolo G, Macchiarella A, et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: Results from a single dose, pilot study. J Urol 2007;178:2040-3.
112. Azadzoi KM. Effect of chronic ischemia on bladder structure and function. Adv Exp Med Biol 2003;539:271-80.
113. Waldkirch E, Uckert S, Yildirim H, et al. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries - Immunohistochemical distribution and functional significance. World J Urol 2005;23:405-10. (Pubitemid 43124392)
114. Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-20.
115. Yono M, Yamamoto Y, Imanishi A, et al. Differential effects of prazosin and naftopidil on pelvic blood flow and nitric oxide synthase levels in spontaneously hypertensive rats. J Recept Signal Transduct Res 2008;28:403-12.
116. Pinggera GM, Mitterberger M, Steiner E, et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: Assessment using colour Doppler ultrasonography. BJU Int 2008;102:470-4. (Pubitemid 352032835)
117. Azadzoi KM, Babayan RK, Kozlowski R, et al. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003;170:659-63. (Pubitemid 36870279)
118. Bertolotto M, Trincia E, Zappetti R, et al. Effect of tadalafil on prostate haemodynamics: Preliminary evaluation with contrast-enhanced US. Radiol Med 2009;114:1106-14.
119. Tsai BM, Turrentine MW, Sheridan BC, et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 2006;81:272-8. (Pubitemid 41815416)
120. Morelli A, Filippi S, Comeglio P, et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010;7:107-20.
121. Roumeguere T, Zouaoui Boudjeltia K, Babar S, et al. Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol 2010;57:522-8.
122. Ahluwalia A, Foster P, Scotland RS, et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 2004;101:1386-91. (Pubitemid 38182698)